Pharmaceutical policy in China

  • Sun Q
  • Santoro M
  • Meng Q
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Contradictory goals plague China's pharmaceutical policy. The government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross-subsidize public hospitals. Yet the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients. The resulting system has distorted market incentives, increased consumers' costs, and financially rewarded inappropriate prescribing, thus undermining public health. Pharmaceuticals account for about half of total health spending in China, representing 43 percent of spending per inpatient episode and 51 percent of spending per outpatient visit. Yet some essential medicines are unavailable or of questionable quality.

Author-supplied keywords

  • China
  • Delivery of Health Care
  • Delivery of Health Care: organization & administra
  • Drug Costs
  • Drug Industry
  • Drug Industry: organization & administration
  • Economic Competition
  • Health Care Reform
  • Health Care Reform: organization & administration
  • Health Expenditures
  • Health Expenditures: trends
  • Health Policy
  • Health Policy: trends
  • Insurance Coverage
  • Insurance Coverage: trends

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Qiang Sun

  • MA Santoro

  • Qingyue Meng

  • Caitlin Liu

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free